Get the Stockscreener App
21.44
1.13%
0.24
Innoviva Inc stock is traded at $21.44, with a volume of 550.44K.
It is up +1.13% in the last 24 hours and down -9.31% over the past month.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
See More
Previous Close:
$21.20
Open:
$21.41
24h Volume:
550.44K
Relative Volume:
0.68
Market Cap:
$1.58B
Revenue:
$434.49M
Net Income/Loss:
$504.34M
P/E Ratio:
3.5651
EPS:
6.0138
Net Cash Flow:
$181.97M
1W Performance:
-1.24%
1M Performance:
-9.31%
6M Performance:
+9.61%
1Y Performance:
+13.32%
1-Day Range:
$21.29
$21.49
1-Week Range:
$21.05
$21.84
52-Week Range:
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
21.44 | 1.58B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | BTIG Research | Buy |
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
INVA|Innoviva Inc|Price:21.440|Chg%:+0.240 - TradingKey
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing - Stock Traders Daily
Innoviva to Participate in Upcoming Investor Conferences - AOL.com
Innoviva (INVA) Leaves Russell Indexes, Is The Stock Still Cheap? - simplywall.st
Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals - ChartMill
Enterprise value to EBITDA forward of Innoviva, Inc. – SWB:HVE - TradingView
Price to sales forward of Innoviva, Inc. – SWB:HVE - TradingView
Innoviva Inc. (INVA) Sees Modest Uptick, Testing Resistance Near $23.43Safe Entry Stocks - dars.gov.et
INVAInnoviva Inc Latest SEC Filings - Finviz
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform? - simplywall.st
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now? - Insider Monkey
5 Cheap Small Cap Stocks to Buy Now - Insider Monkey
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal? - Sahm
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 2000 Growth-Defensive Index - marketscreener.com
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
INVA Forecast — Price Target — Prediction for 2027 - TradingView
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership - Sahm
Enterprise value to EBIT forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout - ChartMill
Price to earnings forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
(INVA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to book forward of Innoviva, Inc. – NASDAQ:INVA - TradingView
Enterprise value to revenue forward of Innoviva, Inc. – GETTEX:HVE - TradingView
Innoviva, Inc. Actuals & Estimates (NASDAQ:INVA) - TradingView
Innoviva, Inc. Actuals & Estimates (DUS:HVE) - TradingView
HVE Forecast — Price Target — Prediction for 2027 - TradingView
Innoviva Inc (INVA) Institutional Confidence - TradingKey
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout | AI
Price to sales forward of Innoviva, Inc. – GETTEX:HVE - TradingView
Innoviva, Inc. Actuals & Estimates (SWB:HVE) - TradingView
Innoviva, Inc. Actuals & Estimates (LS:A2AC9U) - TradingView
A2AC9U Forecast — Price Target — Prediction for 2027 - TradingView
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform - Insider Monkey
BTIG Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Innoviva Inc (INVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally - Insider Monkey
INVA Maintained by BTIG -- Price Target Steady at $42.00 - GuruFocus
H.C. Wainwright Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Innoviva Is Maintained at Buy by BTIG - Moomoo
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform - Investing.com
Innoviva stock trades down to $22.49 as Western Thoracic conference focus draws attention - Traders Union
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):